Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers
- 1 March 2020
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 13 (3), 241-252
- https://doi.org/10.1158/1940-6207.capr-19-0184
Abstract
More than two-thirds of all women diagnosed with epithelial ovarian cancer (EOC) will die from the disease (>14,000 deaths annually), a fact that has not changed considerably in the last three decades. Although the 5-year survival rates for most other solid tumors have improved steadily, ovarian cancer remains an exception, making it the deadliest of all gynecologic cancers and five times deadlier than breast cancer. When diagnosed early, treatment is more effective, with a 5-year survival rate of up to 90%. Unfortunately, most cases are not detected until after the cancer has spread, resulting in a dismal 5-year survival rate of less than 30%. Current screening methods for ovarian cancer typically use a combination of a pelvic examination, transvaginal ultrasonography, and serum cancer antigen 125 (CA125), but these have made minimal impact on improving mortality. Thus, there is a compelling unmet need to develop new molecular tools that can be used to diagnose early-stage EOC and/or assist in the clinical management of the disease after a diagnosis, given that more than 220,000 women are living with ovarian cancer in the United States and are at risk of recurrence. Here, we discuss the state of advancing liquid-based approaches for improving the early detection of ovarian cancer. See all articles in this Special Collection Honoring Paul F. Engstrom, MD, Champion of Cancer PreventionKeywords
Funding Information
- Kansas Institute for Precision Medicine (GM130423)
This publication has 103 references indexed in Scilit:
- Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200Journal of Translational Medicine, 2014
- A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive valueCancer, 2013
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METNature Medicine, 2012
- Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group studyGynecologic Oncology, 2011
- Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumorsGynecologic Oncology, 2011
- Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate CancerJournal of Oncology, 2009
- The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early DetectionPLoS Medicine, 2009
- Ovarian CancerAnnual Review Of Pathology-Mechanisms Of Disease, 2009
- Cancer Screening: A Mathematical Model Relating Secreted Blood Biomarker Levels to Tumor SizesPLoS Medicine, 2008
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerThe New England Journal of Medicine, 2004